Sometimes you have to see it to believe it.
Despite all the signs pointing to a fiery demise for Sanofi-Aventis’ rimonabant (Zimulti), Wall Street still appeared caught off guard...
An FDA advisory committee's recommendation against the approval of Sanofi-Aventis' rimonabant caught many investors off guard. It's hard to believe drug safety issues can still surprise Wall Street, but there are some reasons why analysts lacked clarity on rimonabant.
Sometimes you have to see it to believe it.
Despite all the signs pointing to a fiery demise for Sanofi-Aventis’ rimonabant (Zimulti), Wall Street still appeared caught off guard...
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.